Radiomics-based machine learning (ML) classifier for detection of type 2 diabetes on standard-of-care abdomen CTs: a proof-of-concept study

• Published in: Abdominal imaging 2022-11, Vol.47 (11), p.3806-3816
• Main Authors: Wright, Darryl E., Mukherjee, Sovanlal, Patra, Anurima, Khasawneh, Hala, Korfiatis, Panagiotis, Suman, Garima, Chari, Suresh T., Kudva, Yogish C., Kline, Timothy L., Goenka, Ajit H.
• Format: Article
• Language: English
• Subjects: Abdomen; Antidiabetics; Artificial intelligence; Computed tomography; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - diagnostic imaging; Feature extraction; Gastroenterology; Hepatology; Humans; Hypoglycemic Agents; Imaging; Insulin; Insulins; Machine Learning; Medical imaging; Medicine; Medicine & Public Health; Model testing; Pancreas; Patients; Radiology; Radiomics; Retrospective Studies; Standard of care; Tomography, X-Ray Computed - methods; Training
• ISSN: 2366-0058; 2366-004X; 2366-0058
• DOI: 10.1007/s00261-022-03668-1

Purpose To determine if pancreas radiomics-based AI model can detect the CT imaging signature of type 2 diabetes (T2D). Methods Total 107 radiomic features were extracted from volumetrically segmented normal pancreas in 422 T2D patients and 456 age-matched controls. Dataset was randomly split into training (300 T2D, 300 control CTs) and test subsets (122 T2D, 156 control CTs). An XGBoost model trained on 10 features selected through top-K-based selection method and optimized through threefold cross-validation on training subset was evaluated on test subset. Results Model correctly classified 73 (60%) T2D patients and 96 (62%) controls yielding F1-score, sensitivity, specificity, precision, and AUC of 0.57, 0.62, 0.61, 0.55, and 0.65, respectively. Model’s performance was equivalent across gender, CT slice thicknesses, and CT vendors ( p values > 0.05). There was no difference between correctly classified versus misclassified patients in the mean (range) T2D duration [4.5 (0–15.4) versus 4.8 (0–15.7) years, p  = 0.8], antidiabetic treatment [insulin (22% versus 18%), oral antidiabetics (10% versus 18%), both (41% versus 39%) ( p  > 0.05)], and treatment duration [5.4 (0–15) versus 5 (0–13) years, p  = 0.4]. Conclusion Pancreas radiomics-based AI model can detect the imaging signature of T2D. Further refinement and validation are needed to evaluate its potential for opportunistic T2D detection on millions of CTs that are performed annually.